| Identification | Back Directory | [Name]
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- | [CAS]
2229974-83-6 | [Synonyms]
MS140
XY028-140
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- | [Molecular Formula]
C39H40N10O7 | [MDL Number]
MFCD34187227 | [MOL File]
2229974-83-6.mol | [Molecular Weight]
760.8 |
| Chemical Properties | Back Directory | [density ]
1.482±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 5.56 mg/mL (7.31 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
10.74±0.40(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Biological Activity]
XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].
A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 μμ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 μμ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1]. | [References]
[1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1. |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://www.is0513.com/ShowSupplierProductsList927327/0.htm |
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
|